Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. AVE has ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

For two days, the market did what makes people panic. The semiconductor complex fell 10-14%. The useful question here is, “What is the rest of the market doing while this one group bleeds?" ...

Healthcare veteran Dr Douglas Williams discusses the impact of recent political upheaval in the US and the prospect of major ...

Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...

ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ...

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

Genetic engineering could be used to develop new, more effective production systems for viral vector producing cell lines.

French pharma Ipsen is continuing to expand its product portfolio via M&A deals, today announcing plans to acquire privately-owned Swiss biotech Memo Therapeutics.

Evommune’s recent miss with EVO756's CSU indications is a major setback. Read why I think the selloff in EVMN stock is ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...